Latest News

ToxStrategies scientist publishes new article in the International Journal of Toxicology



ToxStrategies scientist Dr. Brian T. Welsh is the lead author on a new publication describing the preclinical development of Scholar Rock’s investigational product candidate, SRK-181. SRK-181 is a selective TGFβ inhibitor that is being developed to overcome primary resistance to checkpoint inhibitor therapy. Based on preclinical evaluations of SRK-181’s pharmacologic and safety profiles across multiple animal species, SRK-181 may offer an improved safety profile and a wider therapeutic window than non-selective TGFβ inhibitors. 

The article is now available in the International Journal of Toxicology.